AMAG Pharmaceuticals — Q2 2019 Earnings Presentation
26 slides from AMAG Pharmaceuticals's earnings presentation, Aug 7, 2019
Slide 1: AMAG Pharmaceuticals Second Quarter 2019 Financial Results
AMAG Pharmaceuticals Second Quarter 2019 Financial Results August 7, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG
Slide 3: Cautionary Disclosure Regarding AMAG's Long-term Outlook
Cautionary Disclosure Regarding AMAG’s Long-term Outlook AMAG has made forward looking estimates of its long-term outlook, including that it will be adjusted EBITDA neutral by 2020. AMAG’s growth trajectory and expectations for adjusted EBITDA on a multi-year timeframe are based on a strategy of max
Slide 4: Agenda
Agenda 1 Q2-2019 Highlights and Recent Developments 2 Q2-2019 Financial Overview 3 Vyleesi Launch 4 Development Pipeline and Closing Remarks 5 Q&A © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 4
Slide 5: Promoted Products Continue to Grow
Promoted Products Continue to Grow SC Auto-Injector Quarterly Market Share1 Record Revenues & Market Share2 Highest Market Share Since Launch3 5.0% Revenues % % 54 63 YoY: up 12% 4.5% TRx QoQ: grew more than 5% 4.0% NRx 3.5% Market share 3.0% Q1-2019 Q2-2019 17.2% 2Q-2019 avg. market share Jan Feb M
Slide 6: Makena Update
Makena Update Exiting AGx • Sustained IM supply disruption • Loss of IM market share IM market • Increased generic competition FDA scheduled AdCom meeting • FDA to hear from AMAG and experts to PROLONG interpret PROLONG data and inform regulatory decision-making • Tentatively scheduled for Q4-2019 ©
Slide 7: Vyleesi Approved June 21st
VyleesiTM (bremelanotide injection) Approved June 21st Significant Media Coverage Following Approval On Track for National Launch in September Sheryl Kingsberg, a clinical psychologist, said that "the impact of sexual dysfunction on a woman's self-esteem, on her body image, on her self- confidence a
Slide 8: Financial Overview
Financial Overview
Slide 9: Second Quarter Financial Results: Revenue Summary
Second Quarter Financial Results Revenue summary ($M) Q2-2019 Q2-2018 • Makena SC auto-injector revenue continues to grow Makena subcutaneous (SC) $41.0 $13.5 – Increased to $41.0M, up 204% over Q2-2018 and 8.5% auto-injector over Q1-2019 Makena intramuscular (IM) – • Makena IM (10.0) 91.8 branded a
Slide 10: Second Quarter Financial Results: Operating Expense and Income/Loss Summary
Second Quarter Financial Results Operating expense and income/loss summary Three Months Ended June 30, • Decline in CoPS related to decrease in Makena-related amortization, ($M) 2019 2018 partially offset by higher direct CoPS Amortization of intangible assets $3.9 $61.4 • R&D increase primarily rel
Slide 11: 2019 Financial Guidance
2019 Financial Guidance1 6-Mos. Original 2019 Guidance Updated August 2019 Guidance ($M) 2019 Actual2 Low Mid High Low Mid High Total revenue $154 $365 $390 $415 $325 $340 $355 GAAP operating loss ($234) ($206) ($191) ($176) ($286) ($281) ($276) Non-GAAP adjusted EBITDA ($51) ($65) ($50) ($35) ($85)
Slide 12: Strong Balance Sheet
Strong Balance Sheet ($M) 6/30/19 12/31/18 Cash, cash equivalents and investments $2611 $394 Long-term debt: Convertible senior notes (3.25%) due 2022 $320 $320 1 $261M cash balance does not reflect July 2019 $60M milestone payment to Palatin. FINANCIAL OVERVIEW © 2019 AMAG Pharmaceuticals, Inc. All
Slide 13: Vyleesi Launch – September 2019
Vyleesi Launch – September 2019 13
Slide 14: FDA Approved Vyleesi
FDA Approved Vyleesi COMMERCIAL LAUNCH IN SEPTEMBER (not actual size) WOMEN’S HEALTH: VYLEESI © 2019 AMAG Pharmaceuticals, Inc. All rights reserved 14
Slide 15: Early Excitement
Early Excitement 1. AWARENESS 2. EVALUATION 3. CONSIDERATION www STAYING on SITE for 500K over 1 minute 80K visitors to + 51% vs. benchmark symptom checker unblush.com VIEWING at least completions 2 pages/session + 62% vs. benchmark WOMEN’S HEALTH: VYLEESI © 2019 AMAG Pharmaceuticals, Inc. All right
Slide 16: On Track for National Launch in September
On Track for National Launch in September EARLY EXPERIENCE program National LAUNCH ~125 sales representatives on women’s and maternal health salesforce Patients have the opportunity to be among the first to access Vyleesi Sales & marketing teams learn more about the market to refine plans ahead of n
Slide 17: Ensuring Access to Vyleesi for Women with HSDD
Ensuring Access to Vyleesi for Women with HSDD Market Access team focused on securing commercial coverage Launching with copay program: • $0 copay on first Rx • $99 max copay on subsequent refills *Administer subcutaneously as needed at least 45 minutes before anticipated sexual activity. The durati
Slide 18: Ready to Launch Vyleesi in September
Ready to Launch Vyleesi in September Bring first FDA-approved as-needed treatment option to premenopausal women with HSDD Driving awareness of HSDD F O C U S O N Fostering conversations between patients and HCPs Differentiating Vyleesi in marketplace WOMEN’S HEALTH: VYLEESI © 2019 AMAG Pharmaceutica
Slide 19: Development Pipeline Continues to Progress
Development Pipeline Continues to Progress 19
Slide 20: Strong Progress on Strategic Evolution 2017-2022
Strong Progress on Strategic Evolution 2017-2022 Maximizing commercial product opportunities and building the portfolio Approved/ Phase 1 Phase 2 Phase 3 Regulatory Review Marketed Treatment of iron deficiency anemia CKD HEMATOLOGY Treatment to reduce recurrent preterm birth in certain at-risk women
Slide 21: Development Pipeline is Progressing
Development Pipeline is Progressing Commercial products funding investments in development and launch of new products Regulatory Approved/ Phase 1 Phase 2 Phase 3 Review Marketed Treatment of iron deficiency anemia Anticoagulant reversal agent Ciraparantag (potential for orphan drug designation) HEM
Slide 22: Q&A
AMAG Pharmaceuticals Second Quarter 2019 Financial Results Q&A © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 22
Slide 23: Appendix
Appendix 23
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Results
Reconciliation of GAAP to Non-GAAP Financial Results ($M) YTD-2018 YTD-2019 Q2-2018 Q2-2019 GAAP operating income ($8.9) ($233.5) $41.9 ($115.8) Depreciation and intangible asset amortization 114.6 9.1 61.8 4.7 Non-cash inventory step-up adjustments 3.2 -- 1.0 -- Stock-based compensation 9.6 8.7 4.8
Slide 25: Reconciliation of GAAP to Non-GAAP 2019 Financial Guidance
Reconciliation of GAAP to Non-GAAP 2019 Financial Guidance 2019 Financial Guidance ($M) Previous Guidance Revised Guidance Operating loss1 ($206) – ($176) ($286) – ($276) Depreciation & intangible asset amortization 36 18 Stock-based compensation 22 19 Non-cash inventory step up and adjustments to c
Slide 26: AMAG Pharmaceuticals Second Quarter 2019 Financial Results
AMAG Pharmaceuticals Second Quarter 2019 Financial Results August 7, 2019 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2019 reservedAMAG Pharmaceuticals, Inc. All rights reserved 26